Upregulation of ZNRD1 enhances cisplatin resistance in human esophageal cancer cells by regulation of ERCC1 and Bcl-2

Tumor Biology

Volumn 29, Issue 3, 2008, Pages 188-194

  Guo, Wei ^a   Zhao, Yun Ping ^a   Jiang, Yao Guang ^a   Wang, Ru Wen ^a   Hong, Liu ^b   Fan, Dai Ming ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

B Cell lymphoma 2; Cisplatin resistance; Esophageal cancer; Excision repair cross complementing 2; Zinc ribbon domain containing 1 gene

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PROTEIN BAX; PROTEIN BCL 2;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; DNA MICROARRAY; DRUG SENSITIVITY; DRUG TOLERANCE; ESOPHAGUS CANCER; EXPRESSION VECTOR; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NITROBLUE TETRAZOLIUM TEST; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ZINC RIBBON DOMAIN CONTAINING 1 GENE;

EID: 47549105007     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000146864     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med 2003;349:2241-2252.
3. Hwang JJ: Role of chemotherapy in the treatment of gastroesophageal cancers. Oncology 2007;21:579-586.
4. Kartalou M, Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res 2001;478:23-43.
5. Fan W, Wang Z, Kyzysztof F, Prange C, Lennon G: A new zinc ribbon gene (ZNRD1) is cloned from the human MHC class I region. Genomics 2000;63:139-141.
6. Chu TW, Capossela A, Coleman R, Goei VL, Nallur G, Gruen JR: Cloning of a new finger protein gene (ZNF173) within the class I region of the human MHC. Genomics 1995;29:229-239.
7. Qian X, Jeon C, Yoon H, Agarwal K, Weiss MA: Structure of a new nucleic-acid-binding motif in eukaryotic transcriptional elongation factor TFIIS. Nature 1993;365:277-279.
8. Chen HT, Legault P, Glushka J, Omichinski JG, Scott RA: Structure of a (Cys3His) zinc ribbon, a ubiquitous motif in archaeal and eucaryal transcription. Protein Sci 2000;9:1743-1752.
9. Hong L, Zhang Y, Han S, Wang J, Shi Y, Pan Y, Liu N, Zhang X, Fan D: Preparation and characterization of a novel monoclonal antibody specific to human ZNRD1 protein. Hybrid Hybridomics 2004;23:65-68.
10. Hong L, Ning X, Shi Y, Shen H, Zhang Y, Fan D: Reversal of multidrug resistance of gastric cancer cells by downregulation of ZNRD1 with ZNRD1siRNA. Br J Biomed Sci 2004;61:206-210.
11. Hong L, Piao Y, Han Y, Wang J, Zhang X, Du Y, Cao S, Qiao T, Chen Z, Fan D: Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2. Mol Cancer Ther 2005;4:1936-1942.
12. Zhang YM, Zhao YQ, Pan YL, Shi YQ, Jin XH, Yi H, Fan DM: Effect of ZNRD1 gene antisense RNA on drug resistant gastric cancer cells. World J Gastroenterol 2003;9:894-898.
13. Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Döhner H, Cremer T, Lichter P: Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 1997;20:399-407.
14. Hong L, Han Y, Shi R, Shao X, Sun L, Zhang Y, Huang D, Chen Z, Zhang G, Liang J, Hu S, Fan D: ZNRD1 gene suppresses cell proliferation through cell cycle arrest in G1 phase. Cancer Biol Ther 2005;4:61-65.
15. Simon SM, Schindler M: Cell biological mechanism of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994;91:3497-3504.
16. Oka M, Hirazawa K, Yamamoto K, Iizuka N, Hazama S, Suzuki T, Kobayashi N: Induction of Fas-mediated apoptosis on circulating lymphocytes by surgical stress. Ann Surg 1996;223:434-440.
17. Szymkowski DE, Yarema K, Essigmann JM, Lippard SJ, Wood RD: An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proc Natl Acad Sci USA 1992;89:10772-10776.
18. Gosland M, Lum B, Schimmelpfennig J, Baker J, Doukas M: Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 1996;16:16-39.
19. Reardon JT, Vaisman A, Chaney SG, Sancar A: Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-amminedichloro-cyclohexylamine- platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999;59:3968-3971.
20. de Boer J, Hoeijmakers JH: Nucleotide excision repair and human syndromes. Carcinogenesis 2000;21:453-460.
21. Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F, Reed E: Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000;20:645-652.
22. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B, Leichman L: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-316.
23. Welsh C, Day R, McGurk C, Masters JRW, Wood RD, Köberle B: Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 2004;110:352-361.
24. Shi Y, Zhang Y, Zhao Y, Hong L, Liu N, Jin X, Pan Y, Fan D: Overexpression of ZNRD1 promotes multidrug-resistant phenotype of gastric cancer cells through upregulation of P-glycoprotein. Cancer Biol Ther 2004;3:377-381.
25. Chang IY, Kim MH, Kim HB, Lee DY, Kim SH, Kim HY, You HJ: Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 2005;327:225-233.
26. Reed JC: Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17:2941-2953.